Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Public ClinicalTrials.gov record NCT02706717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study was to evaluate whether the probiotic Visbiome Extra Strength reduces inflammation in HIV-infected men and women when compared to a placebo (inactive medication like a dummy pill). The study evaluated whether taking Visbiome Extra Strength by mouth for 24 weeks was safe and well-tolerated for HIV-infected persons on antiretroviral therapy (ART). Probiotics are germs such as yeast or bacteria that are found in food and supplements that are used to improve the health of the digestive system. Many people refer to probiotics as "helpful bacteria." These bacteria live in the body and help the body work normally. In some medical conditions, including HIV infection, helpful bacteria are replaced with bacteria that can change the normal intestinal function and increase inflammation. The investigators tested whether giving a probiotic restored normal intestinal function and decreased inflammation.
Study identification
- NCT ID
- NCT02706717
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 93 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2016 (Actual)
- Primary completion
- Jun 5, 2017 (Actual)
- Completion
- Aug 28, 2017 (Actual)
- Last update posted
- Jan 6, 2020
2016 – 2017
United States locations
- U.S. sites
- 24
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 31788 Alabama CRS | Birmingham | Alabama | 35294 | — |
| UCLA CARE Center CRS (601) | Los Angeles | California | 90095 | — |
| 701 University of California, San Diego AntiViral Research Center CRS | San Diego | California | 92103 | — |
| 801 University of California, San Francisco HIV/AIDS CRS | San Francisco | California | 94110 | — |
| University of Colorado Hospital CRS (6101) | Aurora | Colorado | 80045 | — |
| Northwestern University CRS (2701) | Chicago | Illinois | 60611 | — |
| Rush University Medical Center (2702) | Chicago | Illinois | 60612 | — |
| Johns Hopkins Adult AIDS CRS (201) | Baltimore | Maryland | 21287 | — |
| Washington University CRS (2101) | St Louis | Missouri | 63110 | — |
| 31786 New Jersey Medical School Clinical Research Center CRS | Newark | New Jersey | 07103 | — |
| 7804 Weill Cornell Chelsea CRS | New York | New York | 10010 | — |
| Columbia Physicians and Surgeons CRS (30329) | New York | New York | 10032 | — |
| 7803 Weill Cornell Upton CRS | New York | New York | 10065 | — |
| Unc Aids Crs (3201) | Chapel Hill | North Carolina | 27514 | — |
| Greensboro CRS (3203) | Greensboro | North Carolina | 27401 | — |
| University of Cincinnati CRS (2401) | Cincinnati | Ohio | 45267 | — |
| Case CRS (2501) | Cleveland | Ohio | 44106 | — |
| The Ohio State University AIDS CRS (2301) | Columbus | Ohio | 43210 | — |
| 6201 Penn Therapeutics CRS | Philadelphia | Pennsylvania | 19104 | — |
| Pittsburgh CRS (1001) | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Therapeutics CRS (3652) | Nashville | Tennessee | 37204 | — |
| Trinity Health and Wellness Center CRS (31443) | Dallas | Texas | 75208 | — |
| Houston AIDS Research Team CRS (31473) | Houston | Texas | 77030 | — |
| University of Washington AIDS CRS (1401) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02706717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2020 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02706717 live on ClinicalTrials.gov.